<DOC>
	<DOCNO>NCT00127933</DOCNO>
	<brief_summary>This single arm study stratify patient two treatment cohort base HER2-neu overexpression/amplification . Each cohort independently power primary endpoint . The study evaluate efficacy , safety impact quality life treatment oral Xeloda plus intravenous ( iv ) Taxotere ( docetaxel ) . Patients HER2-neu negative breast cancer receive chemotherapy alone oral Xeloda plus intravenous ( iv ) Taxotere ( docetaxel ) . Patients HER2-neu positive breast cancer , receive chemotherapy combination intravenous ( iv ) Herceptin ( trastuzumab ) . Patients receive 3-weekly cycle treatment Xeloda ( 825mg/m2 oral administration [ po ] twice daily ( bid ) day 1-14 ) + Taxotere ( 75mg/m2 iv day 1 ) . HER2-neu positive patient also receive Herceptin ( load dose 4mg/kg iv follow 2mg/kg iv weekly ) . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>XeNA Study - A Study Xeloda ( Capecitabine ) Patients With Invasive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>woman &gt; =18 year age ; newly diagnose ; infiltrate ( invasive ) HER2neunegative HER2neupositive breast cancer . evidence metastatic disease , except ipsilateral ( side ) axillary lymph node ; previous systemic local primary treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>